GenAI-oneers in Capital Markets

Create a vendor selection project
Click to express your interest in this report
Indication of coverage against your requirements
A subscription is required to activate this feature. Contact us for more info.
Celent have reviewed this profile and believe it to be accurate.
We are waiting for the vendor to publish their solution profile. Contact us or request the RFX.
Projects allow you to export Registered Vendor details and survey responses for analysis outside of Marsh CND. Please refer to the Marsh CND User Guide for detailed instructions.
Download Registered Vendor Survey responses as PDF
Contact vendor directly with specific questions (ie. pricing, capacity, etc)
16 May 2024

Capital Markets FI Survey on GenAI adoption and impact


GenAI has rocketed from moonshot to reality. In this industry of winner takes most, no company wants to be left behind!

To flesh out the reality for FIs in Capital Markets, Celent surveyed buy side, FMI, and sell side executives in roles tied to innovation. Questions included their sentiment towards GenAI, the state of adoption by area, the relevance of use case areas by value chain as well as the success factors they have identified through their experience piloting and implementing GenAI use cases in capital markets.

Survey participants tended to be innovation frontrunners and hence are ahead on the GenAI adoption curve compared to the majority of institutions. Nevertheless, the findings are startling, with a slow start to in production use cases due to accelerate.